未经证实:戈谢病(GD)是一种罕见的常染色体隐性遗传病。1型GD(GD1)是西方国家最普遍的GD形式;酶替代疗法(ERT)是GD1患者的治疗选择。为了了解GD1ERT天鹅胶的经济价值,从美国(US)付款人的角度开发了预算影响模型(BIM)。
UNASSIGNED:我们通过比较当前使用天胶吸收的方案与预计的天胶吸收方案之间的年度总费用,估计了天胶吸收对美国1000万成员健康计划的预算影响。两种方案的总药物成本估计为每种治疗的合格患者数量与每种药物的年度每位患者成本的乘积之和。ERT的平均每位患者费用是通过加上每年的药物采购来计算的,药物管理,和现场护理加价成本。预算影响是在第1-3年衡量的。
UNASSIGNED:估计有65名患者将在第1年接受velaglucerasealfa治疗,到第3年将增加到90名患者。在整个分析中,与imiglucerase(115,909美元)和taliglucerasealfa(80,401美元)相比,velaglucerasealfa实现了成本节约。对于假设的1000万会员的美国健康计划,每年可节省867万美元的总预算,并增加了velaglucerasealfa的吸收。在第1-3年期间,每位成员每月的费用减少了0.0241美元。
UNASSIGNED:BIM结果表明,对于美国卫生计划而言,GD1治疗中增加的velaglucerasealfa摄取可以节省成本。
1型戈谢病(GD1)是一种罕见的遗传性疾病。长期酶替代疗法(ERT)可以逆转和预防并发症。Imiglucerase,taliglucerasealfa,和velaglucerasealfa是3个用于治疗GD1的ERT。在这项研究中,我们估计了velaglucerasealfa的摄取与其他ERT将影响假想的美国医疗保健计划的预算。结果表明,增加velaglucerasealfa的摄取可以节省美国健康计划的成本。
UNASSIGNED: Gaucher disease (GD) is a rare autosomal recessive condition. Type 1 GD (GD1) is the most prevalent form of GD in Western countries; enzyme replacement therapy (ERT) is a treatment option for patients with GD1. To understand the economic value of the GD1 ERT velaglucerase alfa, a budget impact model (BIM) was developed from a United States (US) payer perspective.
UNASSIGNED: We estimated the budget impact of velaglucerase alfa for a 10-million-member US health plan by comparing the annual total costs of therapy between a scenario using current velaglucerase alfa uptake to a projected scenario with increased velaglucerase alfa uptake. Total drug costs for both scenarios were estimated as the sum of the product of the number of eligible patients on each treatment and the annual per-patient cost of each medication. Average per-patient costs for ERTs were calculated by adding the yearly drug acquisition, drug administration, and site-of-care markup costs. The budget impact was measured over years 1-3.
UNASSIGNED: An estimated 65 patients would receive velaglucerase alfa treatment in year 1, increasing to 90 patients by year 3. Across analyses, cost savings were realized with velaglucerase alfa compared with imiglucerase ($115,909) and taliglucerase alfa ($80,401). An annual total budget savings of $8.67 million could be realized for a hypothetical 10-million-member US health plan with increased velaglucerase alfa uptake. The per-member per-month costs decreased by $0.0241 across years 1-3.
UNASSIGNED: BIM results show that increased velaglucerase alfa uptake for GD1 treatment is cost-saving for US health plans.
Type 1 Gaucher disease (GD1) is a rare inherited condition. Long-term enzyme replacement therapy (ERT) can reverse and prevent complications. Imiglucerase, taliglucerase alfa, and velaglucerase alfa are 3 ERTs used to treat GD1. In this study, we estimated how increasing uptake of velaglucerase alfa vs. the other ERTs would impact the budget of a hypothetical US healthcare plan. The results show that increased uptake of velaglucerase alfa is cost-saving for US health plans.